Growth Metrics

Rockwell Medical (RMTI) Current Deferred Revenue (2016 - 2024)

Rockwell Medical filings provide 15 years of Current Deferred Revenue readings, the most recent being $475000.0 for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue rose 932.61% to $475000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $475000.0, a 932.61% increase, with the full-year FY2024 number at $475000.0, up 932.61% from a year prior.
  • Current Deferred Revenue hit $475000.0 in Q4 2024 for Rockwell Medical, up from $46000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $11.1 million in Q2 2020 to a low of $46000.0 in Q3 2023.
  • Median Current Deferred Revenue over the past 5 years was $2.2 million (2020), compared with a mean of $3.5 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 15731.64% in 2020 and later crashed 99.32% in 2023.
  • Rockwell Medical's Current Deferred Revenue stood at $10.2 million in 2020, then dropped by 19.95% to $8.2 million in 2021, then plummeted by 46.9% to $4.3 million in 2022, then tumbled by 98.94% to $46000.0 in 2023, then skyrocketed by 932.61% to $475000.0 in 2024.
  • The last three reported values for Current Deferred Revenue were $475000.0 (Q4 2024), $46000.0 (Q3 2024), and $498000.0 (Q2 2024) per Business Quant data.